Düzeltme: Transplantasyon öncesi fibrinojen ve D-dimer düzeylerinin otolog kök hücre transplantasyonu sonuçlarına etkisi

Yıl 2025, Cilt: 8 Sayı: 5, 952 - 952, 16.09.2025

Neslihan Mandacı Şanlı , Edanur Dilara Mandacı

Bu makalenin ilk hali 30 Temmuz 2025 tarihinde yayımlandı. https://dergipark.org.tr/tr/pub/jhsm/issue/93990/1711682

Düzeltme Notu

Orijinal makalede, ortak yazarlarından biri olan Edanur Dilara Mandacı'nın ORCID numarası, ilgili yazar tarafından yanlış bildirilmiştir. Yazarların talebi üzerine, ORCID numarası doğru bilgileri yansıtacak şekilde düzeltilmiştir. Bu düzeltme, makalenin içeriğini veya sonuçlarını etkilememektedir. Yazarlar bu gözden kaçırma nedeniyle özür dilerler.

Öz

Amaç: Bu çalışmada, hematolojik maligniteler bağlamında otolog hematopoetik kök hücre transplantasyonu (auto-HSCT) uygulanan hastalarda serum D-dimer ve fibrinojen düzeylerinin prognoz üzerindeki etkisinin değerlendirilmesi amaçlanmıştır.

Yöntemler: Bu retrospektif çalışmaya 2010 ile 2024 yılları arasında auto-HSCT uygulanan 152 yetişkin hasta dahil edilmiştir. Transplantasyon öncesi D-dimer ve fibrinojen düzeyleri kaydedilmiştir. Sağkalım analizleri Kaplan–Meier eğrileri ve Cox regresyon yöntemleriyle yapılmıştır. ROC analizi ile eşik değerler belirlenmiştir.

Bulgular: D-dimer ve fibrinojen için sırasıyla >860 ng/mL ve >448 mg/dL eşik değerleri, artmış nüks ve mortalite oranları ile istatistiksel olarak anlamlı bulunmuştur. D-dimer ve fibrinojen düzeyleri mortalite (HR: 96.74 ve 5.478) ve nüks (HR: 24.254 ve 6.921) açısından bağımsız prediktörler olarak belirlenmiştir. Bu biyobelirteçlerin yüksek seviyeleri, beş yıllık genel sağkalım oranlarını anlamlı şekilde azaltmıştır.

Sonuç: Yüksek D-dimer ve fibrinojen düzeylerine sahip auto-HSCT hastalarının prognozu olumsuzdur ve transplantasyon sonuçları kötüdür. Bu biyobelirteçlerin ucuz ve erişilebilir olması, transplantasyon öncesi risk sınıflaması yapılarak hedefe yönelik tedavi planlamasında kolaylık sağlar.

Anahtar Kelimeler

Otolog kök hücre transplantasyonu , D-dimer , Fibrinojen , Prognoz , Hematolojik malignite

Düzeltme: The impact of pre-transplant fibrinogen and D-dimer levels on transplantation outcomes in autologous stem cell transplantation

Bu makalenin ilk hali 30 Temmuz 2025 tarihinde yayımlandı. https://dergipark.org.tr/tr/pub/jhsm/issue/93990/1711682

Düzeltme Notu

In the original article, the ORCID of one of the co-authors, Edanur Dilara Mandacı, was incorrectly reported by the corresponding author. At the request of the authors, the ORCID has been corrected to reflect the accurate information. This correction does not affect the content or conclusions of the article. The authors apologize for this oversight.

Öz

Aims: Determine how serum D-dimer and fibrinogen levels affect the prognosis of patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) within the context of underlying hematologic malignancies.
Methods: This retrospective study included 152 adult patients who received auto-HSCT between 2010 and 2024. D-dimer and fibrinogen levels were documented prior to the transplant. Survival analyses were performed with Kaplan-Meier curves and Cox regression methods. ROC analysis provided cut-off values.
Results: The D-dimer and fibrinogen cut-off levels of >860 ng/ml and >448 mg/dl, respectively, were statistically significant with increased rates of relapse and mortality. Mortality was independently predicted by D-dimer and fibrinogen (HR: 96.74 and 5.478) and relapse (HR: 24.254 and 6.921). Increased levels of the markers significantly reduced the five-year overall survival.
Conclusion: Auto-HSCT patients with elevated D-dimer and fibrinogen have unfavorable prognoses and poor outcomes. The inexpensive nature of these biomarkers allows greater ease in establishing risk stratification for targeted pre-transplant planning.

Anahtar Kelimeler

Autologous stem cell transplantation , D-dimer , fibrinogen , prognosis , hematologic malignancy

Etik Beyan

This study was approved by the Erciyes University Clinical Research Ethics Committee (Approval No: 2025/31, Date: 22.01.2025).

Destekleyen Kurum

The authors received no financial support for the research, authorship, and/or publication of this article.

Kaynakça

• Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44. doi:10.1038/s41408-019-0205-9
• Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217-226. doi:10.1007/s11899-017-0382-1
• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. doi:10. 1182/blood.2020008824
• Linkins LA, Takach Lapner S. Review of D-dimer testing: good, bad, and ugly. Int J Lab Hematol. 2017;39(Suppl 1):98-103. doi:10.1111/ijlh.12665
• Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411-2420. doi:10.1016/j.jacc.2017.09.024
• Franchini M, Focosi D, Pezzo MP, Mannucci PM. How we manage a high D-dimer. Haematologica. 2023;109(4):1035-1045. doi:10.3324/haematol.2023.283966
• Schafer K, Goldschmidt E, Oostra D, Fish J, Russell T, Lurie F. The clinical significance of ultra-high D-dimer levels. J Vasc Surg Venous Lymphat Disord. 2022;10(1):8-13. doi:10.1016/j.jvsv.2021.06.011
• Ozen M, Yilmaz A, Cakmak V, et al. D-dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021;40:55-59. doi: 10.1016/j.ajem.2020.12.023
• He X, Yao F, Chen J, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11(1):1830. doi:10.1038/s41598-021-81300-w
• Fan BE, Lippi G, Favaloro EJ. D-dimer levels for the exclusion of pulmonary embolism: making sense of international guideline recommendations. J Thromb Haemost. 2024;22(3):604-608. doi:10.1016/j.jtha.2023.12.015
• Cosmi B, Legnani C, Libra A, Palareti G. D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications. Pol Arch Intern Med. 2023;133(11):16604. doi:10.20452/pamw.16604
• Mandacı Şanlı N, Keklik M, Ünal A. Pretransplant serum fibrinogen level may be a predictive marker on chronic graft-versus-host disease (cGVHD) in patients having undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). Int J Hematol Oncol. 2022;32(1):1-8.
• Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5(Suppl 1):246-254. doi:10.1111/j.1538-7836.2007. 02497.x
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47. doi:10.1056/nejmoa1703327
• Go SI, Lee MJ, Lee WS, et al. D-dimer can serve as a prognostic and predictive biomarker for metastatic gastric cancer treated by chemotherapy. Medicine (Baltimore). 2015;94(30):e951. doi:10.1097/MD. 0000000000000951
• Bi XW, Wang L, Zhang WW, et al. High pretreatment D-dimer levels correlate with adverse clinical features and predict poor survival in patients with natural killer/T-cell lymphoma. PLoS One. 2016;11(3): e0152842. doi:10.1371/journal.pone.0152842
• Batschauer AP, Figueiredo CP, Bueno EC, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21(6):1267-1272. doi:10.1093/annonc/mdp474
• Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost. 2005;3(8):1618-1627. doi:10.1111/j.1538-7836.2005.01416.x
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444. doi:10.1038/nature072 05
• Kleber M, Ihorst G, Terhorst M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1(9):e35-38. doi:10.1038/bcj.2011.34
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-Specific Comorbidity Index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919. doi:10.1182/blood-2005-05-2004
• Fukumoto K, Taniguchi T, Usami N, et al. Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer. Surg Today. 2015;45(1):63-67. doi: 10.1007/s00595-014-0894-4
• Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20(3):170-175. doi:10.1097/MBC.0b013e32831bc2de
• Mandacı Şanlı N, Keklik M, Ünal A. Role of uric acid levels as a prognostic indicator in allogeneic hematopoietic stem cell transplantation: insights from a single-center study. Cumhuriyet Med J. 2024;46(2):121-128. doi: 10.7197/cmj.1428410